# Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

> **NCT00501332** · PHASE2 · UNKNOWN · sponsor: **Maxygen Holdings Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Chemotherapy-Induced Neutropenia
- Breast Cancer

## Interventions

- **BIOLOGICAL:** Maxy-G34

## Key facts

- **NCT ID:** NCT00501332
- **Lead sponsor:** Maxygen Holdings Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2007-12-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00501332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00501332, "Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00501332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*